OFG
NTLA icon

Orcam Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Orcam Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,650
Closed -$204K – 34
2022
Q3 		$204K Buy
+3,650
New +$226K 0.35% 26
2022
Q2 		– Sell
-3,150
Closed -$229K – 34
2022
Q1 		$229K Hold
3,150
– – 0.33% 29
2021
Q4 		$372K Buy
+3,150
New +$395K 0.51% 23

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Orcam Financial Group's NTLA Position: Q4 2022 in Review

Orcam Financial Group sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 3,650 shares — an estimated $204K sold.

Orcam Financial Group first reported a position in NTLA in Q4 2021 and held it in 3 quarters. The position peaked at $372K in Q4 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Orcam Financial Group reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Orcam Financial Group sold 3,650 Intellia Therapeutics shares in Q4 2022, an estimated $204K.
  • Orcam Financial Group first reported a position in Intellia Therapeutics in Q4 2021 and held it in 3 quarters.
  • Orcam Financial Group's Intellia Therapeutics position peaked at $372K in Q4 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Orcam Financial Group's 13F filing for Q4 2022, filed 30 Jan 2023.